


Resistência aos Antibióticos


Programa da Aula

- Introdução
- Mecanismos de Resistência a Antimicrobianos
- Origem de Resistência a Antimicrobianos
- Método de Medição da Resistência Bacteriana




Uso Indiscriminado de Antibióticos em Animais

“Estudos apontam relação entre uso de antibióticos em animais e resistência a medicamentos em seres humanos”




Exemplo: Animais de corte tratados com o glicopeptídeo avoparcina constituem um potencial reservatório de infecção por *Enterococcus* resistente à vancomicina (VRE) em humanos.

Desenvolvimento de Novas Drogas



The diagram illustrates the drug development process as a funnel. It is divided into Pre-clinical studies and Clinical trials. Pre-clinical studies include Chemistry (Search for active substances, Application for patent), Pharmacology (Toxicological effects studies on various kinds of animals), and Industrial (Authorisation process). Clinical trials include Phase I (Study of effects on healthy human subjects, 20-50 people), Phase II (Limited study of patients, 50-100 patients), Phase III (Comparative studies on a large number of patients, 200-1000), NDA (Authorisation process (New Drug Application)), and Phase IV (Continued comparative studies). The funnel narrows from 2-4 years and \$50 million in the early stages to 2-3 years and \$150 million in the final stages. A red area at the bottom indicates the 'Level of knowledge' increasing over time.

Desenvolvimento de Novas Drogas



The timeline shows the following antibiotic classes and their approximate development periods:

- Sulfa drugs: 1940-1950
- β -lactams: 1940-1950
- Chloramphenicol, Tetracyclines: 1940-1950
- Aminoglycosides: 1950-1960
- Macrolides: 1950-1960
- Glycopeptides: 1960-1970
- Quinolones, Streptogramins: 1970-1980
- Oxazolidinones: 2000-2010
- Lipopeptides: 2000-2010
- Mullins: 2000-2010

The bar chart shows the total number of new antibacterial agents from 1983 to 2004. The number of agents peaks around 1993 and then shows a significant decline, illustrating the innovation gap.





CAUSES OF ANTIBIOTIC RESISTANCE





HANDLE ANTIBIOTICS WITH CARE





Antibiotic resistance happens when bacteria change and become resistant to the antibiotics used to treat the infections they cause.





- Over-prescribing of antibiotics
- Patients not finishing their treatment
- Over-use of antibiotics in livestock and fish farming
- Poor infection control in hospitals and clinics
- Lack of hygiene and poor sanitation
- Lack of new antibiotics being developed



www.who.int/drugresistance
#AntibioticResistance
World Health Organization











- Mecanismos de Resistência a Antimicrobianos**
- Alteração do alvo
 - Enzimas inativadoras ou modificadoras
 - Bombas de efluxo
 - Impermeabilidade do envoltório celular

1 – Alteração do alvo




- Por alteração da sequência de aminoácidos da proteína alvo;
- Por modificação química do alvo mediada por enzimas.


★ Exemplos:

- ◆ β-lactâmicos
- ◆ Glicopeptídeos
- ◆ Sulfonamidas
- ◆ Rifampicina
- ◆ Quinolonas
- ◆ Aminoglicosídeos


Formação do Peptidoglicano e Ação de Antimicrobianos que Agem na Parede Celular



Formação do Peptidoglicano e Ação de Antibióticos que Agem na Parede Celular



Resistência Mediada por Alteração de Alvo



Resistência Mediada por Alteração de Alvo

Glicopeptídeo: Vancomicina

N-acyl-D-Ala-D-Ala N-acyl-D-Ala-D-Lac

- *Enterococcus* resistente à vancomicina (VRE)

2 – Enzimas inativadoras

★ Exemplos:

- ◆ **β-lactâmicos**
- ◆ **Aminoglicosídeos**
- ◆ **Clorafenicol**

Resistência Mediada por β-lactamases

Porinas (canais) β-lactâmico Membrana Externa

β-lactamase

Membrana Interna

PBP Síntese peptidoglicana

Peptidoglicana

Resistência Mediada por Enzimas Inativadoras (hidrólise)

β-lactâmicos

Penicilinas

Cefalosporinas

Monobactams

Carbapenems

R = cadeia lateral

β-lactamases

- Classe A ou grupo II: hidrolisam penicilinas e cefalosporinas
- Classe B ou grupo III: hidrolisam carbapenêmicos
- Classe C ou grupo I: hidrolisam cefalosporinas
- Classe D: hidrolisam penicilinas e cloxacilina
- Grupo IV: hidrolisam penicilina

IMPORTANTE: β-lactamases de amplo espectro ou espectro estendido (ESBL – Extended Spectrum β-lactamases)

Resistência Mediada por Enzimas Inativadoras

Aminoglicosídeos

Clorafenicol

3 – alteração na permeabilidade da membrana

★ Exemplos:

- β-lactâmicos
- Aminoglicosídeos
- Quinolonas

Resistência mediada por alteração de permeabilidade

Porina alterada

β-lactâmico

Membrana Externa

Membrana Interna

PBP

Síntese peptidoglicana

Peptidoglicana

Resistência mediada por alteração de permeabilidade

Outer membrane

Inner membrane

Periplasm

Normal synthesis of wild-type porins

Decreased synthesis of wild-type porins

Normal synthesis of restricted-channel porins

Normal synthesis of mutated porins

Normal synthesis of wild-type porins with a channel blocker

Diminuição da expressão de OmpF leva a resistência a:



- quinolonas
- tetraciclina
- clorafenicol
- β-lactâmicos

4 . Efluxo



★ Exemplos:

- ◆ Tetraciclina
- ◆ β-lactâmicos
- ◆ Cloranfenicol
- ◆ Quinolonas



Origem da Resistência a Antimicrobianos

Aspectos relacionados à resistência aos antimicrobianos em bactérias




★ Origem da Resistência





- ♦ resistência cromossomal
- ♦ resistência extracromossomal

★ Mecanismos de transmissão

- ♦ transmissão vertical
- ♦ transmissão horizontal

➤ Resistência Intrínseca e Extrínseca





Método de Medição da Resistência Bacteriana


Métodos de Medição de Resistência




Métodos de Medição de Resistência

- **Método qualitativo:** Método de difusão com discos de Kirby-Bauer
- **Método quantitativo:** Macrodiluição.

Antibiograma




Macrodiluição



MIC

Concentração de Ampicilina (µg/mL)

Teste de difusão em disco de ágar




Plano de iniciativas para vencer a resistência

Problema:  **2.049.442 doenças**

 **2.023.000 mortes**

Plano de iniciativas para vencer a resistência

- Estabelecimento de Programas de Prevenção, grupos dedicados à educação em saúde, prevenir infecções



Plano de iniciativas para vencer a resistência

- Detectar e responder rapidamente para reduzir a MDR em gonorréia;
- Identificar intervenções críticas contra *M. tuberculosis* multi-resistentes, expandir avaliação de imigrantes e refugiados;



Plano de iniciativas para vencer a resistência

Avaliar impacto dos antibióticos no microbioma e avaliar como usar os microrganismos para controle

